Edition:
United Kingdom

Roche Holding AG (ROG.S)

ROG.S on Virt-X Level 1

244.20CHF
2:13pm BST
Change (% chg)

CHF5.65 (+2.37%)
Prev Close
CHF238.55
Open
CHF238.00
Day's High
CHF244.65
Day's Low
CHF237.90
Volume
1,425,557
Avg. Vol
1,522,630
52-wk High
CHF252.85
52-wk Low
CHF206.35

Select another date:

Wed, Oct 17 2018

BRIEF-Roche CEO Says 'Confidence Rising' in Sales Growth in 2019, Beyond

* CEO SAYS HIS CONFIDENCE RISING QUARTER-BY-QUARTER THAT DRUGMAKER WILL CONTINUE SALES GROWTH IN 2019, BASED ON TRIAL RESULTS; "WE ARE SURE WE CAN OUTGROW THE IMPACT OF BIOSIMILARS"

BRIEF-Roche CEO Says Confident In Ability To Sustain Growth Beyond 2018

* SHARES SEEN RISING 1.9 PERCENT AFTER Q3 RESULTS - PREMARKET INDICATORS

BRIEF-Roche Launches Tumor Tissue Analysis Kits For Oncology Research

* ROCHE LAUNCHES NGS AVENIO TUMOR TISSUE ANALYSIS KITS FOR ONCOLOGY RESEARCH

CORRECTED-UPDATE 1-U.S. FDA panel backs Celltrion copycat of Roche blood cancer drug

Oct 10 Celltrion Inc's biosimilar of Roche Holding AG's blockbuster cancer drug, Rituxan, on Wednesday won unanimous backing from an advisory panel to the U.S. Food and Drug Administration.

CORRECTED-U.S. FDA panel backs Celltrion copycat drug of Roche blood cancer drug

Oct 10 An advisory panel to the U.S. Food and Drug Administration on Wednesday voted unanimously in favor of Celltrion Inc's copycat drug of Roche Holding AG's blood cancer drug Rituxan.

U.S. FDA panel backs Celltrion copycat of Roche blood cancer drug

Celltrion Pharm Inc's biosimilar of Roche Holding AG's blockbuster cancer drug, Rituxan, on Wednesday won unanimous backing from an advisory panel to the U.S. Food and Drug Administration.

U.S. FDA panel backs Celltrion copycat drug of Roche blood cancer drug

Oct 10 An advisory panel to the U.S. Food and Drug Administration on Wednesday voted unanimously in favor of Celltrion Pharm Inc's copycat drug of Roche Holding AG's blood cancer drug Rituxan.

BRIEF-Roche Updates Data On Ocrevus To Treat Multiple Sclerosis

* OCREVUS (OCRELIZUMAB) DATA SHOW EARLY INITIATION OF TREATMENT REDUCES DISABILITY PROGRESSION OVER FIVE YEARS IN RELAPSING AND PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS Source text for Eikon: Further company coverage:

BRIEF-Roche To Present New Data From Cancer Immunotherapy Programme at ESMO

* ROCHE TO PRESENT NEW POSITIVE DATA FROM ITS BROAD CANCER IMMUNOTHERAPY PROGRAMME

BRIEF-Go Therapeutics Enters Into Agreement With Roche For Glycotargeting Bispecific Cancer Treatment

* GO THERAPEUTICS ENTERS INTO A LICENSE AGREEMENT WITH ROCHE FOR NEW GLYCOTARGETING BISPECIFIC CANCER TREATMENT

Select another date: